Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - saxagliptinum - filmtabletten - saxagliptinum 2.5 mg ut saxagliptini hydrochloridum, lactosum monohydricum 99.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.95 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, e 171, talcum, e 172 (flavum), acidum hydrochloridum, drucktinte: e 132, lacca, pro compresso obducto. - antidiabetikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - saxagliptinum - filmtabletten - saxagliptinum 5.0 mg ut saxagliptini hydrochloridum, lactosum monohydricum 99.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.95 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (rubrum), acidum hydrochloridum, drucktinte: e 132, lacca, pro compresso obducto. - antidiabetikum - synthetika

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - saxagliptinhydrochlorid - filmtablette - saxagliptinhydrochlorid (35995) 2,789 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

h e x a l aktiengesellschaft (3079284) - saxagliptinhydrochlorid - filmtablette - saxagliptinhydrochlorid (35995) 5,578 milligramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - saxagliptin hydrochlorid - filmtablette - 2,5 mg - saxagliptin hydrochlorid 2.789 mg - saxagliptin

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - saxagliptin hydrochlorid - filmtablette - 5 mg - saxagliptin hydrochlorid 5.578 mg - saxagliptin